Nuclear Medicine and Biology
Volume 37, Issue 3 , Pages 317-326 , April 2010

Combination therapy in A549 cells

Received 17 September 2009 ,Revised 26 November 2009 ,Accepted 27 November 2009.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249
  2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106–130
  3. Stackhouse MA, Buchsbaum DJ, Kancharla SR, Grizzle WE, Grimes C, Laffoon K, et al. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. Cancer Gene Ther. 1999;6(3):209–219
  4. Buchsbaum DJ. Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. Semin Nucl Med. 2004;34(1):32–46
  5. Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine. 2003;20(3):255–264
  6. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198
  7. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32(2):84–91
  8. Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm. 2003;18(4):601–609
  9. Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res. 2003;63(20):6864–6869
  10. Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med. 2002;32(2):92–96
  11. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–658
  12. Thakur M, Kolan H, Rifat S, et al. Vapreotide labeled with Tc for imaging tumours: preparation and preliminary evaluation. Int J Oncol. 1996;9:445–451
  13. Mather SJ, Ward BG. High efficiency iodination of monoclonal antibodies for radiotherapy. J Nucl Med. 1987;28(6):1034–1036
  14. Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, Nexo E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res. 2009;69(3):873–878
  15. Shao W, Zhao S, Liu Z, Zhang J, Ma S, Sato JD, et al Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochem Biophys Res Commun. 2006;349(2):816–824
  16. Charland S, Boucher MJ, Houde M, Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology. 2001;142(1):121–128
  17. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther. 2000;1(4):376–382
  18. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978;298(25):1384–1386
  19. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994;54(13):3455–3459
  20. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab. 1995;80(9):2806–2814
  21. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab. 2000;85(7):2564–2571
  22. Giannetti N, Enjalbert A, Krantic S. Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: relevance of the adenylyl cyclase stimulation. J Cell Biochem. 2000;78(4):666–673
  23. Lachowicz-Ochedalska A, Rebas E, Kunert-Radek J, Winczyk K, Pawlikowski M. Effects of somatostatin and its analogues on tyrosine kinase activity in rodent tumors. Biol Signals Recept. 2000;9(5):255–259
  24. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med. 1998;217(2):143–152
  25. Zalatnai A, Szegedi Z, Bocsi J. Flow cytometric evidence of apoptosis in human pancreatic cancer xenografts treated with Sandostatin (octreotide). Anticancer Res. 2000;20(3A):1663–1666
  26. Lal S, Lauer UM, Niethammer D, Beck JF, Schlegel PG. Suicide genes: past, present and future perspectives. Immunol Today. 2000;21(1):48–54
  27. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst. 1996;88(17):1193–1203
  28. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A. 1994;91(17):8302–8306
  29. Warmann SW, Armeanu S, Heigoldt H, Ruck P, Vonthein R, Heitmann H, et al Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro. Pediatr Blood Cancer. 2009;53(2):145–151
  30. Lv SQ, Zhang KB, Zhang EE, Gao FY, Yin CL, Huang CJ, et al. Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study. Med Sci Monit. 2009;15(1):BR13–BR20
  31. Wu DH, Liu L, Chen LH. Antitumor effects and radiosensitization of cytosine deaminase and thymidine kinase fusion suicide gene on colorectal carcinoma cells. World J Gastroenterol. 2005;11(20):3051–3055
  32. Pandha HS, Cook D, Greenhalgh R, Dalgleish A. Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy. BJU Int. 2005;95(9):1336–1343

☆ This study was supported by the National Natural Science Foundation of China (project nos. 30570526 and 30770598).

PII: S0969-8051(09)00289-3

doi: 10.1016/j.nucmedbio.2009.11.009

Nuclear Medicine and Biology
Volume 37, Issue 3 , Pages 317-326 , April 2010

Article Tools

* Image Usage & Resolution